APC and neoplasm: The presence of selected disruptive mutations was not linked to patient sex in the entire dataset, nor to tumor stage in READ, although in COAD, two mutations remained differently distributed across tumor stages after multiple testing corrections: the ACVR2A mutations were linked to earlier tumor stages (stages I/II, p = 0.007) while the APC mutations were associated with an advanced disease (stage IV, p = 0.008).